Meldonium Cycling - Frequently Asked Questions

How to take Mildronate: before or after meals?

Mildronate desirable to apply to the food, but the efficiency will not change, if we take a capsule or syrup after meals.

Can I take Mildronate with other medications?

On the application Mildronate with other drugs, consult with your doctor!

Mildronate enhances the action vasodilatig funds, some antihypertensive drugs, cardiac glycosides. It can be combined with antianginal drugs, anticoagulants, antiagregaentami, antiarrhythmics, diuretics, bronchodilators.

In view of the possible development of mild tachycardia and hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents and peripheral vasodilators.

Can I use Mildronate during pregnancy?

Clinical studies on the safety of use during pregnancy has not been carried out. Therefore, the drug is not recommended for use in accordance with the instructions for medical use of the drug Mildronate now, to avoid undesirable effects on the mother and fetus during pregnancy.

It is not clear whether the drug is excreted in breast milk. If treatment with Mildronate mother is necessary, breast-feeding is stopped.

Can you give Mildronate children?
Mildronat successfully applied in medical practice in children younger than 12 years, but unfortunately, no one has ever collected enough data that would officially allow the reception Mildronate® children.

Application Mildronate officially allowed teenagers between 12 and 16 years in the following indications: functional disorders of the cardiovascular system, cardiomyopathy (post-miocardic, metabolic, neurogenic, dyshormonal, toxic), decreased performance, mental and physical overload.

Does medication Meldonium has side effects?
Of particular note Mildronate safety of the drug, it is - one of the most important factors explaining its widespread acceptance among physicians and patients. Mildronate Security confirmed periodically updated safety reports and the results of published clinical studies.

Side effects are rare, can be expressed as an allergic reaction (redness, rash, itching, swelling), as well as dyspepsia, tachycardia, changes in blood pressure, agitation.

Patients with chronic diseases of the liver and kidneys should be careful with long-term use of the drug.

Experience in the treatment of acute myocardial infarction and unstable angina suggests that trimethylhydrasine propionate dihydrate is not a first-line drug for acute coronary syndrome.

No information about adverse effects on the reaction rate Mildronate.

In some cases, it is not recommended to use Mildronate?
Mildronate not recommended for use in women during pregnancy and lactation.

Mildronate also contraindicated in individuals with hypersensitivity to meldonium and some other component of the drug.

Contraindications to increased intracranial pressure (in violation of the venous outflow, intracranial tumors).

In addition, there is not enough data on the use of the drug in children younger than 12 years.

Do Mildronate affect the ability to drive a vehicle?
Studies on the effect of the application of Mildronate on the ability to drive have been conducted.

Passed whether the drug is standardized according to international quality standards?
Production of all the products of JSC "Grindeks", including drugs Mildronate takes place according to generally accepted standards of Good Manufacturing Practice of pharmaceuticals, which guarantee high quality products. JSC «Grindeks» held regular inspections and audits by regulators around the world, including Russia, Japan and the United States.
Where the drug Meldonium is released?
The drug is available only on the industries in the European Union - in Latvia and Slovakia.

In which countries is used Mildronate?
Mildronate drugs registered and sold in Latvia, Lithuania, Russia and other CIS countries. As the drug is registered in Albania, Kosovo and Mongolia.
Registration processes are underway in other countries. Today, JSC "Grindeks" evaluates the possibility of starting the drug registration Mildronate in Europe.